Franklin Resources’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-133,410
Closed -$3.38M 2922
2024
Q3
$3.38M Sell
133,410
-8,341
-6% -$216K ﹤0.01% 1525
2024
Q2
$3.59M Buy
141,751
+1,246
+0.9% +$32.3K ﹤0.01% 1457
2024
Q1
$3.57M Buy
140,505
+6,894
+5% +$167K ﹤0.01% 1495
2023
Q4
$3.03M Buy
133,611
+19,276
+17% +$399K ﹤0.01% 1264
2023
Q3
$2.13M Sell
114,335
-14,968
-12% -$310K ﹤0.01% 1372
2023
Q2
$3.36M Hold
129,303
﹤0.01% 1235
2023
Q1
$3.71M Buy
129,303
+15,649
+14% +$466K ﹤0.01% 1176
2022
Q4
$3.36M Buy
113,654
+41
+0% +$1.17K ﹤0.01% 1225
2022
Q3
$2.7M Buy
113,613
+36,751
+48% +$846K ﹤0.01% 1252
2022
Q2
$1.72M Sell
76,862
-2,450
-3% -$54.7K ﹤0.01% 1404
2022
Q1
$1.99M Buy
79,312
+14,420
+22% +$440K ﹤0.01% 1416
2021
Q4
$2.33M Buy
64,892
+17,500
+37% +$700K ﹤0.01% 1457
2021
Q3
$2.02M Hold
47,392
﹤0.01% 1452
2021
Q2
$2.05M Hold
47,392
﹤0.01% 1355
2021
Q1
$1.93M Buy
47,392
+10,392
+28% +$394K ﹤0.01% 1349
2020
Q4
$1.68M Sell
37,000
-21
-0.1% -$797 ﹤0.01% 1324
2020
Q3
$1.31M Buy
37,021
+21
+0.1% +$759 ﹤0.01% 1329
2020
Q2
$1.34M Buy
+37,000
New +$1.22M ﹤0.01% 1222

Other funds holding ANIK

Franklin Resources's ANIK Position: Q4 2024 in Review

Franklin Resources sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 133,410 shares — an estimated $3.38M sold.

Franklin Resources first reported a position in ANIK in Q2 2020 and held it in 18 quarters. The position peaked at $3.71M in Q1 2023. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Franklin Resources reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Franklin Resources sold 133,410 Anika Therapeutics shares in Q4 2024, an estimated $3.38M.
  • Franklin Resources first reported a position in Anika Therapeutics in Q2 2020 and held it in 18 quarters.
  • Franklin Resources's Anika Therapeutics position peaked at $3.71M in Q1 2023.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Franklin Resources's 13F filing for Q4 2024, filed 12 Feb 2025.